3aZEVvoRtp6McXy8TuIlR6lERn067Z

Investor Relations

NYSE: NVRO

Price

89.91 +0.60 ( +0.67% ) 4:02 9/20/19 Pricing delayed 20 minutes

Volume 374,727

Recent News

See All
August 28, 2019 Nevro Announces Completion of Patient Enrollment in Largest Multicenter Randomized Controlled Trial of High Frequency Spinal Cord Stimulation for Painful Diabetic Neuropathy
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain conditions, today announced that it has completed patient enrollment in its prospective, multicenter Randomized Controlled Trial (RCT) for the treatment of chronic pain for patients who suffer from Painful Diabetic Neuropathy (PDN). "This is an important step in the evaluation of Nevro's Senza HF10 therapy for this very large and often undertreated patient population," said D. Keith Grossman, Nevro's Chairman, CEO and President.  "Diabetes affects nearly one in ten adults in the United States and can damage peripheral nerves, resulting in severe pain and numbness in the hands and feet.  According to published literature, there are approximately 4 million diabetic patients suffering from painful diabetic neuropathy in the U.S. alone.  The SENZA-PDN study compares HF10 therapy plus Conventional Medical Management (CMM) to CMM alone in 216...
August 23, 2019 Nevro to Present at Morgan Stanley 17th Annual Healthcare Conference
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the Company will be participating in the Morgan Stanley 17 th Annual Healthcare Conference in New York City. Nevro Chairman, CEO and President D. Keith Grossman is scheduled to present on Monday, September 9, 2019 at 2:50 pm Eastern Time. A live webcast of the presentation, as well as an archived recording, will be available on the "Investors" section of the Company's website at www.nevro.com. About Nevro Corp.
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The Senza® System...
August 8, 2019 Nevro Reports Second Quarter 2019 Financial Results
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported financial results for the second quarter ended June 30, 2019. Revenue for the second quarter of 2019 was $93.6 million, a 3% decrease compared to $96.1 million during the prior year period. U.S. revenue for the second quarter of 2019 was $78.1 million, a 2% decrease compared to $79.9 million in the prior year period. The year-over-year decrease in U.S. revenue was primarily driven by the impact of customer destocking associated with the Company's previously announced decision to alter its practice regarding certain high-volume product orders.  International revenue was $15.5 million compared to $16.2 million in the prior year period. This represents a 4% decrease on an as-reported basis and a 2% increase on a constant currency basis. "Our second quarter 2019 financial results demonstrate sequential improvement across the...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Senza, Senza II, HF10, More, Nevro, Nevrocloud, Surpass and the Nevro, HF10, and Frequency Pairing Logos are trademarks of Nevro Corp.